


Searching News Database: Schering AG
HSMN NewsFeed - 17 Jun 2021
KaliVir Immunotherapeutics Appoints Drs. Terry Hermiston and Jon Wigginton to Board of Directors
KaliVir Immunotherapeutics Appoints Drs. Terry Hermiston and Jon Wigginton to Board of Directors
HSMN NewsFeed - 4 Feb 2019
Sojournix Appoints Ruth Thieroff-Ekerdt, M.D. As Senior Vice President And Chief Medical Officer
Sojournix Appoints Ruth Thieroff-Ekerdt, M.D. As Senior Vice President And Chief Medical Officer
HSMN NewsFeed - 13 Feb 2013
Lpath Promotes Leigh Hsu, Ph.D., to Vice President of Corporate Development
Lpath Promotes Leigh Hsu, Ph.D., to Vice President of Corporate Development
HSMN NewsFeed - 21 Sep 2010
Jeffrey A. Winton Named Vice President of Communications at Eli Lilly and Company
Jeffrey A. Winton Named Vice President of Communications at Eli Lilly and Company
HSMN NewsFeed - 10 Dec 2008
MorphoSys Appoints Dr. Arndt Schottelius as Chief Development Officer and Member of the Management Board
MorphoSys Appoints Dr. Arndt Schottelius as Chief Development Officer and Member of the Management Board
HSMN NewsFeed - 22 Sep 2008
Medimetriks Pharmaceuticals, Inc. Welcomes Wolfgang Kunze to Its Board of Directors
Medimetriks Pharmaceuticals, Inc. Welcomes Wolfgang Kunze to Its Board of Directors
HSMN NewsFeed - 8 Jul 2008
Agile Therapeutics Appoints Senior Executive Jeffrey Frick as Chief Business Officer
Agile Therapeutics Appoints Senior Executive Jeffrey Frick as Chief Business Officer
HSMN NewsFeed - 26 Sep 2007
Titan Adds Dr. Marc Rubin to Executive Management Team as President and Chief Executive Officer
Titan Adds Dr. Marc Rubin to Executive Management Team as President and Chief Executive Officer
HSMN NewsFeed - 3 Jun 2007
Xanthus Announces Phase 1 Results for P2045 - a Targeted Agent for Non-Small Cell Lung Cancer
Xanthus Announces Phase 1 Results for P2045 - a Targeted Agent for Non-Small Cell Lung Cancer
HSMN NewsFeed - 25 Apr 2007
Alkermes and Indevus Announce Initiation of Phase 2a Clinical Study of ALKS 27 for the Treatment of COPD
Alkermes and Indevus Announce Initiation of Phase 2a Clinical Study of ALKS 27 for the Treatment of COPD
HSMN NewsFeed - 5 Feb 2007
Cardium and InnerCool Announce New External and Internal Patient Temperature Modulation Systems
Cardium and InnerCool Announce New External and Internal Patient Temperature Modulation Systems
HSMN NewsFeed - 1 Feb 2007
VioQuest Pharmaceuticals, Inc. Announces Appointment of Chief Scientific Officer
VioQuest Pharmaceuticals, Inc. Announces Appointment of Chief Scientific Officer
HSMN NewsFeed - 14 Dec 2006
EPIX Pharmaceuticals to File Appeal with the Center for Drug Evaluation and Research for Vasovist(TM)
EPIX Pharmaceuticals to File Appeal with the Center for Drug Evaluation and Research for Vasovist(TM)
HSMN NewsFeed - 23 Nov 2006
Betaferon(R) Approved in Australia for Earliest Stages of Multiple Sclerosis
Betaferon(R) Approved in Australia for Earliest Stages of Multiple Sclerosis
HSMN NewsFeed - 20 Nov 2006
Actelion Announces Definitive Agreement to Acquire U.S.-Based CoTherix, Inc.
Actelion Announces Definitive Agreement to Acquire U.S.-Based CoTherix, Inc.
HSMN NewsFeed - 13 Nov 2006
Treatment of Diabetic Foot Ulcers to Be Addressed at Upcoming American Heart Association Meeting
Treatment of Diabetic Foot Ulcers to Be Addressed at Upcoming American Heart Association Meeting
HSMN NewsFeed - 9 Nov 2006
Bayer Outlines New Global R&D Structures; U.S. Pharma Sites and Future Headquarters
Bayer Outlines New Global R&D Structures; U.S. Pharma Sites and Future Headquarters
HSMN NewsFeed - 31 Oct 2006
Berlex Oncology Evaluating Combination Therapy for Common Form of Non-Hodgkin's Lymphoma
Berlex Oncology Evaluating Combination Therapy for Common Form of Non-Hodgkin's Lymphoma
HSMN NewsFeed - 23 Oct 2006
FDA Approves Betaseron(R) for Use After the First Event Suggestive of Multiple Sclerosis
FDA Approves Betaseron(R) for Use After the First Event Suggestive of Multiple Sclerosis
HSMN NewsFeed - 20 Oct 2006
Indevus Announces the Finalization of Supply Agreement with Schering AG, Germany for NEBIDO(R)
Indevus Announces the Finalization of Supply Agreement with Schering AG, Germany for NEBIDO(R)
HSMN NewsFeed - 17 Oct 2006
Inovio Biomedical Acquires Rights to DNA Vaccine Licenses and Intellectual Property from Valentis
Inovio Biomedical Acquires Rights to DNA Vaccine Licenses and Intellectual Property from Valentis
HSMN NewsFeed - 12 Oct 2006
KaloBios Pharmaceuticals Appoints David W. Pritchard as President and Chief Executive Officer
KaloBios Pharmaceuticals Appoints David W. Pritchard as President and Chief Executive Officer
HSMN NewsFeed - 18 Sep 2006
Bausch & Lomb Licenses SEGRA Compound From Schering AG for Ophthalmic Use
Bausch & Lomb Licenses SEGRA Compound From Schering AG for Ophthalmic Use
HSMN NewsFeed - 15 Sep 2006
Schering AG and AstraZeneca Form Strategic Alliance to Develop Novel Anti-Cancer Drug
Schering AG and AstraZeneca Form Strategic Alliance to Develop Novel Anti-Cancer Drug
HSMN NewsFeed - 6 Sep 2006
Xanthus Pharmaceuticals Licenses Novel Cancer Targeting Agents From Schering AG, Berlin
Xanthus Pharmaceuticals Licenses Novel Cancer Targeting Agents From Schering AG, Berlin
HSMN NewsFeed - 20 Jul 2006
Berlex Issues Nationwide Recall of a Single Lot of Ultravist(R) Injection 370 mgI/mL, 125 mL in the U.S.
Berlex Issues Nationwide Recall of a Single Lot of Ultravist(R) Injection 370 mgI/mL, 125 mL in the U.S.
HSMN NewsFeed - 30 Jun 2006
EPIX Pharmaceuticals Files Appeal with FDA Regarding Vasovist(TM) Approvable Letters
EPIX Pharmaceuticals Files Appeal with FDA Regarding Vasovist(TM) Approvable Letters
HSMN NewsFeed - 26 Jun 2006
NexMed Announces Termination of Alprox-TD Agreement With Schering AG and Provides Operational Update
NexMed Announces Termination of Alprox-TD Agreement With Schering AG and Provides Operational Update
HSMN NewsFeed - 1 Jun 2006
Dr. Gabor Rubanyi of Berlex Biosciences Joins Cardium as Chief Scientific Officer
Dr. Gabor Rubanyi of Berlex Biosciences Joins Cardium as Chief Scientific Officer
HSMN NewsFeed - 22 May 2006
Xanthus Pharmaceuticals Appoints John Lister-James, Ph.D. as Vice President, Development
Xanthus Pharmaceuticals Appoints John Lister-James, Ph.D. as Vice President, Development
Additional items found! 242
Members Archive contains
242 additional stories matching:
Schering AG
(Password required)
Schering AG
(Password required)
